Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as a… Read more
Connect Biopharma Holdings Ltd (CNTB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.314x
Based on the latest financial reports, Connect Biopharma Holdings Ltd (CNTB) has a cash flow conversion efficiency ratio of -0.314x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.41 Million) by net assets ($55.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Connect Biopharma Holdings Ltd - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Connect Biopharma Holdings Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Connect Biopharma Holdings Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Connect Biopharma Holdings Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Madison County Financial Inc
PINK:MCBK
|
0.004x |
|
Turk Ilac ve Serum Sanayi AS
IS:TRILC
|
0.023x |
|
Actinium Pharmaceuticals Inc
NYSE MKT:ATNM
|
-0.459x |
|
Mermaid Maritime Public Company Limited
PINK:MMMPF
|
-0.015x |
|
Harmony Electronics
TWO:8182
|
-0.019x |
|
Tamul Multimedia Co. Ltd
KQ:093640
|
-0.020x |
|
Business Online PCL
BK:BOL
|
0.012x |
|
Sol Strategies Inc. Common Shares
NASDAQ:STKE
|
-0.026x |
Annual Cash Flow Conversion Efficiency for Connect Biopharma Holdings Ltd (2018–2024)
The table below shows the annual cash flow conversion efficiency of Connect Biopharma Holdings Ltd from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $92.17 Million | $-23.61 Million | -0.256x | +45.99% |
| 2023-12-31 | $101.04 Million | $-47.93 Million | -0.474x | +23.45% |
| 2022-12-31 | $160.21 Million | $-99.27 Million | -0.620x | +69.01% |
| 2021-12-31 | $272.57 Million | $-544.93 Million | -1.999x | -1325.81% |
| 2020-12-31 | $-157.01 Million | $-25.61 Million | 0.163x | -46.10% |
| 2019-12-31 | $-43.27 Million | $-13.09 Million | 0.303x | -91.49% |
| 2018-12-31 | $-19.41 Million | $-69.03 Million | 3.556x | -- |